NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6
EMERYVILLE, Calif.--(BUSINESS WIRE)--Aug 30, 2018--NovaBay ® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.C. Wainwright 20 th Annual Global Investment Conference on Thursday, September 6, 2018 at 2:35 p.m. Eastern time (5:35 p.m. Pacific time). The conference is being held at the St. Regis New York in New York City.
A live webcast and replay will be available on the Investors section of the Company’s website at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics ®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX ® family of products and the AGANOCIDE ® compounds. The Neutrox family of products includes AVENOVA ® for the eye care market, NEUTROPHASE ® for wound care market, and CELLERX ® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180830005065/en/
CONTACT: NovaBay Pharmaceuticals, Inc.
For NovaBay Avenova+ purchasing information:
Please call us toll free: 1-800-890-0329 or email email@example.com
From the Company:
Jack McGovern, 510-899-8800
Chief Financial Officer
LHA Investor Relations
Jody Cain, 310-691-7100
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY OPTICAL PHARMACEUTICAL OTHER HEALTH OTHER SCIENCE SCIENCE
SOURCE: NovaBay Pharmaceuticals, Inc.
Copyright Business Wire 2018.
PUB: 08/30/2018 08:00 AM/DISC: 08/30/2018 08:01 AM